Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Conditions

• Non-Small Cell Lung Cancer Stage IIIB
• Non-small Cell Lung Cancer Stage IV
• EGFR T790M

Interventions

• DRUG: Osimertinib
• DRUG: Aspirin

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University